Autolus Therapeutics plc 8-K

What Happened
Autolus Therapeutics plc (AUTL) announced on January 12, 2026 (filed on Form 8‑K) preliminary unaudited net product revenue for AUCATZYL® (obe-cel) of approximately $24 million for Q4 2025 and approximately $75 million for full-year 2025. The company provided 2026 AUCATZYL net revenue guidance of $120 million to $135 million and said current and projected cash, cash equivalents and marketable securities are expected to fund operations into the fourth quarter of 2027. A press release and an updated corporate presentation (to be used at the J.P. Morgan Health Conference) were furnished as Exhibits 99.1 and 99.2.

Key Details

• Preliminary unaudited AUCATZYL net product revenue: ~ $24M (Q4 2025); ~ $75M (FY 2025).
• 2026 AUCATZYL net revenue guidance: $120M–$135M (announced Jan 12, 2026).
• Cash runway: Company expects existing cash, cash equivalents and marketable securities, together with projected AUCATZYL revenues and operating plans, to fund operations into Q4 2027.
• Materials: Press release and updated investor presentation posted/used at J.P. Morgan Health Conference (Exhibits 99.1, 99.2).

Why It Matters
These preliminary results show a meaningful revenue ramp for AUCATZYL from 2025 to 2026 — the guidance implies roughly a 60%–80% year‑over‑year increase versus the reported 2025 total — and the stated cash runway reduces near‑term financing risk through late 2027 if plans hold. For retail investors, the items to watch next are the final audited results, execution against the 2026 revenue guidance, and any updates at upcoming investor meetings or conference presentations.